77 related articles for article (PubMed ID: 6309380)
1. Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection.
Young CW; Schneider R; Leyland-Jones B; Armstrong D; Tan CT; Lopez C; Watanabe KA; Fox JJ; Philips FS
Cancer Res; 1983 Oct; 43(10):5006-9. PubMed ID: 6309380
[TBL] [Abstract][Full Text] [Related]
2. Metabolic competition studies of 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine in vero cells and herpes simplex type 1-infected vero cells.
Chou TC; Lopez C; Colacino JM; Feinberg A; Watanabe KA; Fox JJ; Philips FS
Mol Pharmacol; 1984 Nov; 26(3):587-93. PubMed ID: 6092904
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the antiherpetic activity of 2'-fluoro-5-iodo-ara-C in rabbit eyes and cell cultures.
Trousdale MD; Nesburn AB; Watanabe KA; Fox JJ
Invest Ophthalmol Vis Sci; 1981 Dec; 21(6):826-32. PubMed ID: 6273355
[TBL] [Abstract][Full Text] [Related]
4. 2'Fluoro-5-iodo-arabinosyl-cytosine: a new agent for herpes infections in the immunosuppressed patient.
Donner AL; Leyland-Jones B
Drug Intell Clin Pharm; 1984 Nov; 18(11):885-8. PubMed ID: 6094133
[TBL] [Abstract][Full Text] [Related]
5. [(E)-5-(2-bromovinyl)-2'-desoxyuridine--a new nucleoside analog with selective inhibitory action against herpesviruses. Studies in cell culture and animal experiments].
Reefschläger J; Wutzler P; Thiel KD; Töpke H; Bärwolff D; Langen P
Pharmazie; 1987 Jun; 42(6):407-11. PubMed ID: 2823299
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections.
Feinberg A; Leyland-Jones B; Fanucchi MP; Hancock C; Fox JJ; Watanabe KA; Vidal PM; Williams L; Young CW; Philips FS
Antimicrob Agents Chemother; 1985 May; 27(5):733-8. PubMed ID: 2990323
[TBL] [Abstract][Full Text] [Related]
7. 2'-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster.
Leyland-Jones B; Donnelly H; Groshen S; Myskowski P; Donner AL; Fanucchi M; Fox J
J Infect Dis; 1986 Sep; 154(3):430-6. PubMed ID: 3525694
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study.
Spriggs DR; Robbins G; Takvorian T; Kufe DW
Cancer Res; 1985 Aug; 45(8):3932-6. PubMed ID: 4016760
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
12. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens.
Engelmann I; Petzold DR; Kosinska A; Hepkema BG; Schulz TF; Heim A
J Med Virol; 2008 Mar; 80(3):467-77. PubMed ID: 18205230
[TBL] [Abstract][Full Text] [Related]
13. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
14. [Clinical picture of Herpesviridae infections among immunocompromised patients: bone marrow and solid organ transplants recipients].
Simon K; Dziemianko I
Przegl Epidemiol; 2003; 57(2):289-97. PubMed ID: 12910597
[TBL] [Abstract][Full Text] [Related]
15. Radiosynthesis of F-18 labeled cytidine analog 2'-fluoro-5-iodo-l-beta-d-arabinofuranosylcytosine ([(18)F]FIAC).
Wu CY; Chan PC; Chang WT; Liu RS; Alauddin MM; Wang HE
Appl Radiat Isot; 2009; 67(7-8):1362-5. PubMed ID: 19324560
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation.
Gómez E; Laurés A; Baltar JM; Melón S; Díez B; de Oña M
Transplant Proc; 2005 Nov; 37(9):3760-3. PubMed ID: 16386530
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB/c mice.
Kuo YC; Lee YC; Leu YL; Tsai WJ; Chang SC
Antiviral Res; 2008 Nov; 80(2):206-12. PubMed ID: 18621082
[TBL] [Abstract][Full Text] [Related]
18. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Reusser P; Cordonnier C; Einsele H; Engelhard D; Link D; Locasciulli A; Ljungman P
Bone Marrow Transplant; 1996 May; 17(5):813-7. PubMed ID: 8733703
[TBL] [Abstract][Full Text] [Related]
19. Advances in antiviral therapy.
Wu JJ; Pang KR; Huang DB; Tyring SK
Dermatol Clin; 2005 Apr; 23(2):313-22. PubMed ID: 15837157
[TBL] [Abstract][Full Text] [Related]
20. Treatment of varicella-zoster with cytosine arabinoside.
Hall TC; Wilfert C; Jaffe N; Traggis D; Lux S; Rompf P; Katz S
Trans Assoc Am Physicians; 1969; 82():201-10. PubMed ID: 4316122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
